Dienstag, 31. Juli 2007

Idenix Writes Off Hepatitis Drug Subsequently FDA Reexamine

"I think this drug will have no time to come in encourage clinical development" Idenix Pharmaceuticals Inc. said on Fri it has written off its experimental hepatitis C drug subsequently U.S. regulators ruled that the risks connected with the drug outweigh the benefits. via Reuters